Impax Asset Management Group plc reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 42.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,000 shares of the biotechnology company’s stock after selling 55,000 shares during the quarter. Impax Asset Management Group plc owned about 0.37% of Ligand Pharmaceuticals worth $23,428,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Ligand Pharmaceuticals by 5.7% during the 2nd quarter. GAMMA Investing LLC now owns 681 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 37 shares during the last quarter. Choreo LLC grew its stake in Ligand Pharmaceuticals by 3.0% during the 3rd quarter. Choreo LLC now owns 1,634 shares of the biotechnology company’s stock worth $510,000 after buying an additional 47 shares during the last quarter. Cim Investment Management Inc. grew its stake in Ligand Pharmaceuticals by 3.4% during the 1st quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company’s stock worth $296,000 after buying an additional 49 shares during the last quarter. Ethic Inc. grew its stake in Ligand Pharmaceuticals by 7.4% during the 3rd quarter. Ethic Inc. now owns 1,002 shares of the biotechnology company’s stock worth $313,000 after buying an additional 69 shares during the last quarter. Finally, BTG Pactual Asset Management US LLC increased its position in Ligand Pharmaceuticals by 7.1% during the 2nd quarter. BTG Pactual Asset Management US LLC now owns 1,123 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 74 shares in the last quarter. 91.28% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on LGND shares. Citigroup increased their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. Barclays boosted their price target on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 11th. Royal Bank Of Canada upped their price objective on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $358.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Ligand Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $355.38.
Ligand Pharmaceuticals Trading Down 2.6%
NASDAQ:LGND opened at $293.81 on Wednesday. The company has a market capitalization of $5.88 billion, a P/E ratio of 131.17, a PEG ratio of 5.27 and a beta of 1.16. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71. Ligand Pharmaceuticals Incorporated has a 12 month low of $175.89 and a 12 month high of $326.63. The firm has a fifty day simple moving average of $302.13 and a 200-day simple moving average of $259.07.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.34. The firm had revenue of $78.75 million for the quarter, compared to the consensus estimate of $77.00 million. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The firm’s revenue was down 31.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.09 EPS. On average, equities research analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.
Insider Transactions at Ligand Pharmaceuticals
In other news, insider Andrew Reardon sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $313.22, for a total value of $1,566,100.00. Following the transaction, the insider directly owned 31,854 shares of the company’s stock, valued at approximately $9,977,309.88. This represents a 13.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Aryeh sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total value of $960,150.00. Following the completion of the transaction, the director owned 105,476 shares of the company’s stock, valued at approximately $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 24,093 shares of company stock worth $7,384,287. 5.60% of the stock is owned by insiders.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
